DeepMed Research

Bintrafusp alfa

Generic Name: Bintrafusp alfa

Drug Type: Biotech

CAS Number: 1918149-01-5

Unique Ingredient Identifier: NW9K8C1JN3

Background: Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).

Clinical Trials

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: bintrafusp alfa

First Posted Date: 2020-06-11

Last Posted Date: 2022-04-06

Lead Sponsor: UNICANCER

Target Recruit Count: 7

Registration Number: NCT04428047

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Institut de cancérologie de Lorraine, Vandoeuvre les nancy, France

and more 5 locations

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

Phase 2

Recruiting

Conditions: Recurrent Thymoma
Thymic Epithelial Tumor
Thymic Cancer

Interventions: Drug: M7824

First Posted Date: 2020-06-05

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT04417660

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma
Recurrent Carcinoma
Metastatic Cancer
Non-keratinizing Carinoma

Interventions: Drug: Bintrafusp Alfa

First Posted Date: 2020-05-21

Last Posted Date: 2024-05-09

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 38

Registration Number: NCT04396886

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Stage IIIA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma
Stage IIIC Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8

Interventions: Drug: Bintrafusp Alfa
Drug: Docetaxel

First Posted Date: 2020-05-20

Last Posted Date: 2024-01-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 10

Registration Number: NCT04396535

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: Bintrafusp alfa

First Posted Date: 2020-04-16

Last Posted Date: 2024-04-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 25

Registration Number: NCT04349280

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Phase 1

Terminated

Conditions: Histologically or Cytologically Confirmed Pancreatic Cancer
Unresectable or Borderline Resectable Pancreatic Cancer
Pancreatic Neoplasms
Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions: Drug: M7824
Drug: M9241
Radiation: SBRT

First Posted Date: 2020-03-31

Last Posted Date: 2022-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT04327986

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Phase 1

Recruiting

Conditions: Kaposi Sarcoma

Interventions: Drug: NHS-IL12
Drug: M7824

First Posted Date: 2020-03-10

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT04303117

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bioimaging Study of 89Zr-M7824 in NSCLC

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Combination Product: 89Zirconium-M7824
Drug: M7824

First Posted Date: 2020-03-05

Last Posted Date: 2023-01-17

Lead Sponsor: Olivia Newton-John Cancer Research Institute

Target Recruit Count: 5

Registration Number: NCT04297748

Locations: 🇦🇺
Austin Health, Heidelberg, Victoria, Australia

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Phase 1

Active, not recruiting

Conditions: Cervical Cancer
Oropharyngeal Cancer
Anal Cancer
HPV Cancers
Vulvar, Vaginal, Penile, Rectal Cancer

Interventions: Biological: PDS0101
Biological: M7824
Biological: NHS-IL12

First Posted Date: 2020-02-27

Last Posted Date: 2025-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT04287868

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Phase 1

Completed

Conditions: Head and Neck Cancer
Head and Neck Neoplasms

Interventions: Drug: M7824
Biological: TriAd vaccine
Drug: N803

First Posted Date: 2020-01-30

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT04247282

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy